[SCHEDULE 13G/A] Qualigen Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Alpha Capital Anstalt has filed Amendment No. 2 to Schedule 13G for Qualigen Therapeutics (QLGN).

• Beneficial ownership: 36,434 common shares.
• Ownership percentage: 2.223 % of the 1,635,475 shares outstanding as of 18 Jul 2025.
• Voting & dispositive power: Sole power over all reported shares; no shared power.
• Filer details: Liechtenstein entity, address Altenbach 8, FL-9490 Vaduz.
• Purpose: Certified as a passive investment with no intent to influence control.

The update simply records Alpha Capital’s sub-5 % stake; it carries limited strategic or valuation implications for QLGN shareholders.

Insights

Securities Analyst

TL;DR: Filing shows Alpha Capital’s passive 2.223 % stake in QLGN; below 5 % threshold, minimal market impact.

The amendment confirms Alpha Capital Anstalt now holds 36,434 QLGN shares with sole voting and dispositive authority. At 2.223 % of outstanding equity, the position is well under the 5 % level that typically signals potential influence. The certification of passive intent further reduces governance significance. Absent evidence of recent buying or selling velocity, the disclosure is routine and should not materially affect liquidity, float, or strategic optionality. Therefore, investor reaction is expected to be muted.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

QUALIGEN THERAPEUTICS, INC.

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

74754R103

(CUSIP Number)

07/21/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74754R103

1

Names of Reporting Persons

Alpha Capital Anstalt

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LIECHTENSTEIN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 36,434.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 36,434.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

36,434.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.223 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to 5, 7, 9 and 11: Based on 1,635,475 shares outstanding as of July 18, 2025 as reported on Form 10-Q filed with the Securities and Exchange Commission on July 21, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: QUALIGEN THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 2042 Corte Del Nogal, Carlsbad, California 92011
Item 2.
(a)	Name of person filing: Alpha Capital Anstalt
(b)	Address or principal business office or, if none, residence: Altenbach 8, FL-9490 Vaduz, Liechtenstein
(c)	Citizenship: Liechtenstein
(d)	Title of class of securities: COMMON STOCK, $0.001 PAR VALUE PER SHARE
(e)	CUSIP No.: 74754R103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 36,434.00
(b)	Percent of class: 2.223%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 36,434.00
	(ii) Shared power to vote or to direct the vote: 0 Shares
	(iii) Sole power to dispose or to direct the disposition of: 36,434.00
	(iv) Shared power to dispose or to direct the disposition of: 0 Shares
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alpha Capital Anstalt

Signature:	/s/ Konrad Ackermann
Name/Title:	Konrad Ackermann/Director
Date:	08/07/2025

FAQ

How many Qualigen Therapeutics (QLGN) shares does Alpha Capital own?

Alpha Capital Anstalt reports 36,434 common shares of QLGN.

What percentage of QLGN’s outstanding stock does this represent?

The stake equals 2.223 % of the 1,635,475 shares outstanding as of July 18 2025.

Does Alpha Capital have control over the shares?

Yes. It has sole voting and dispositive power over all 36,434 shares and no shared authority.

Is Alpha Capital seeking to influence Qualigen Therapeutics’ management?

No. The certification states the shares are held solely for passive investment, not to influence control.

Why was an amendment to Schedule 13G filed?

Amendment No. 2 updates Alpha Capital’s ownership, now below the 5 % threshold, ensuring compliance with SEC disclosure rules.